Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
45 hedge funds and large institutions have $471M invested in Odonate Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 7 closing their positions.
271% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 7
73% more funds holding
Funds holding: 26 → 45 (+19)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
13% less capital invested
Capital invested by funds: $541M → $471M (-$69.4M)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.7M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$4.95M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.4M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$2.36M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.28M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.15M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$1.25M |
| 4 |
SCM
Sio Capital Management
New York
|
-$1.25M |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$878K |
ODT Hedge Fund Activity: Q1 2018 in Review
45 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q1 2018, worth a combined $471M — down 13% from $541M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ODT positions and 7 closed out — a net gain of 19 holders — while 7 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $6.7M. The largest seller was Millennium Management, exiting entirely with an estimated $2.28M sold.
- 45 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q1 2018, up from 26 in Q4 2017.
- Funds reported $471M of Odonate Therapeutics, Inc. Common Stock stock for Q1 2018, down 13% quarter-over-quarter.
- 26 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q1 2018 and 7 closed out, a net change of +19 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q1 2018 was BlackRock, an estimated $6.7M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q1 2018 was Millennium Management, an estimated $2.28M sold.
Based on aggregated 13F filings for Q1 2018.